|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
L04AA34
|
|
gptkbp:brand
|
alemtuzumab
|
|
gptkbp:CASNumber
|
216503-57-0
|
|
gptkbp:chemicalFormula
|
C6428H9956N1714O2016S40
|
|
gptkbp:contraindication
|
HIV infection
active infection
|
|
gptkbp:cost
|
high
|
|
gptkbp:halfLife
|
2 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lemtrada
|
|
gptkbp:indication
|
relapsing forms of multiple sclerosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:mechanismOfAction
|
gptkb:monoclonal_antibody
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:riskEvaluationMitigationStrategy
|
required in US
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
autoimmune disorders
thyroid disorders
infections
infusion reactions
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
CD52
|
|
gptkbp:UNII
|
J39AR2B3D0
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:赛诺菲
|
|
gptkbp:bfsLayer
|
6
|